FDA Required Outcomes Data For Cleviprex Priority Review, Proposed Label
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA’s determination that The Medicines Company’s Cleviprex did not actually show a significant benefit over other intravenous antihypertensives caused the agency to make a rare move, and downgrade the application from a priority to a standard review.